Facebook
Twitter
LinkedIn
ForwardChemotherapy and Immunotherapy for Urologists and Advanced Practice Providers (APPs) Webcast (2025)
This course is taught by an interdisciplinary group of MDs and APPs and intended for a mixed audience of similar backgrounds. It describes in detail the treatment options for advanced and metastatic prostate, bladder, and kidney cancer, including non-muscle invasive bladder cancer. Up-to-date NCCN and AUA guidelines are utilized to guide the course. Because of the disease states and spaces that are the focus, most of the therapies that are taught are systemic, including cytotoxic chemotherapy, targeted biologic therapy, and immunotherapy, or more specifically check-point inhibitors. The indications, mechanisms, efficacy, and side effects are discussed, including the clinical trials that led to the approval of the individual therapies. At the end of the course, cases are presented, and the course instructors serve as a panel to reveal how they would manage specific clinical scenarios with regard to concepts discussed in the course. This is a valuable learning opportunity that focuses on therapies that are not necessarily administered by urologists/urologic oncologists, but which we must be familiar with in a multidisciplinary clinical setting.
ACKNOWLEDGEMENTS:
This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Identify the guidelines for first-line and beyond treatment of patients with hormone-sensitive advanced and metastatic prostate cancer, including medications, their mechanism, side effects and efficacy.
- Summarize the recommendations for first-line and beyond treatment of castrate-resistant metastatic and nonmetastatic prostate cancer, including medications, their mechanism, side effects and efficacy.
- Diagram the treatment options for high-risk non-muscle invasive bladder cancer.
- Distinguish the guideline-defined therapeutic options for locally advanced and metastatic bladder cancer.
- Discuss treatment options for locally advanced and metastatic kidney cancer, including medications, their mechanism, side effects and efficacy.
FACULTY DISCLOSURES
| Name | Company Name | Relationship Type | End Date |
| Dunn, Mary W. | No relevant financial relationships to disclose | ||
| Lallas, Costas D. | No relevant financial relationships to disclose | ||
| Trabulsi, Edouard J. | CG Oncology | Consultant or Advisor | Current |
EDUCATION COUNCIL DISCLOSURE
Education Council Disclosures_June 2024.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Workgroup Disclosures_June 2024.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
ACCREDITATION INFORMATION
Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Release Date: May, 2025
Expiration Date: May, 2026
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation